The company’s late-stage breast cancer development portfolio comprises enobosarm, a selective androgen receptor targeting agonist.

In January 2022, Veru entered into a collaboration and supply agreement with Eli Lilly, with the latter supplying abemaciclib for the ENABLAR-2 trial.